KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Treasury Shares: 2019-2025

Historic Treasury Shares for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $2.6 million.

  • Royalty Pharma's Treasury Shares fell 1.73% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 1.73%. This contributed to the annual value of $2.7 million for FY2024, which is 1.26% up from last year.
  • As of Q3 2025, Royalty Pharma's Treasury Shares stood at $20.5 million, which was down 4.65% from $21.5 million recorded in Q2 2025.
  • Royalty Pharma's Treasury Shares' 5-year high stood at $21.5 million during Q2 2025, with a 5-year trough of $3.1 million in Q2 2024.
  • For the 3-year period, Royalty Pharma's Treasury Shares averaged around $10.4 million, with its median value being $8.6 million (2023).
  • Per our database at Business Quant, Royalty Pharma's Treasury Shares rose by 25.63% in 2021 and then fell by 6.31% in 2023.
  • Quarterly analysis of 5 years shows Royalty Pharma's Treasury Shares stood at $2.7 million in 2021, then climbed by 3.35% to $2.8 million in 2022, then decreased by 6.31% to $2.6 million in 2023, then rose by 1.26% to $2.7 million in 2024, then decreased by 1.73% to $2.6 million in 2025.
  • Its Treasury Shares stands at $2.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.7 million for Q1 2025.